LCG
FOLD

Lisanti Capital Growth’s Amicus Therapeutics FOLD Stock Holding History

Lisanti Capital Growth’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-203,755
Closed -$4.71M – 150
2020
Q4 		$4.71M Buy
+203,755
New +$4.17M 0.65% 63
2018
Q2 		– Sell
-87,495
Closed -$1.32M – 143
2018
Q1 		$1.32M Buy
+87,495
New +$1.33M 0.64% 69

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lisanti Capital Growth's FOLD Position: Q1 2021 in Review

Lisanti Capital Growth sold out of Amicus Therapeutics (FOLD) in Q1 2021, closing a stake of 203,755 shares — an estimated $4.71M sold.

Lisanti Capital Growth first reported a position in FOLD in Q1 2018 and held it in 2 quarters. The position peaked at $4.71M in Q4 2020. 259 funds tracked by Wall St. Rank hold FOLD as of Q1 2021.

  • Lisanti Capital Growth reported no remaining Amicus Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Lisanti Capital Growth sold 203,755 Amicus Therapeutics shares in Q1 2021, an estimated $4.71M.
  • Lisanti Capital Growth first reported a position in Amicus Therapeutics in Q1 2018 and held it in 2 quarters.
  • Lisanti Capital Growth's Amicus Therapeutics position peaked at $4.71M in Q4 2020.
  • 259 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2021.

Based on Lisanti Capital Growth's 13F filing for Q1 2021, filed 12 May 2021.